Overview

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis

Status:
Active, not recruiting
Trial end date:
2022-10-26
Target enrollment:
Participant gender:
Summary
This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer